Conmed

CNMDNYSE
$67.51
0.470.70%
At Close: -
$67.51
00.00%
After Hours: 1:00 PM EDT
15 minutes delayed
Conmed (CNMD) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$160.00
Lowest Price Target1
$75.00
Consensus Price Target1
$109.80

Conmed (NYSE:CNMD) Stock, Analyst Ratings, Price Targets, Predictions

Conmed Corp has a consensus price target of $109.8, established from looking at the 39 latest analyst ratings. The last 3 analyst ratings were released from Needham, JP Morgan, and Wells Fargo on May 6, 2024, April 25, 2024, and April 25, 2024. With an average price target of $86.33 between Needham, JP Morgan, and Wells Fargo, there's an implied 27.88% upside for Conmed Corp from these 3 analyst ratings.

Analyst Trends and Forecast
2
1
Feb
2
1
Apr
0
0
0
0
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.3
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
JP Morgan
Wells Fargo
Piper Sandler
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Conmed

Buy NowGet Alert
05/06/2024Buy Now58.5%Needham
Mike Matson
 → $107ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now11.09%JP Morgan
Robbie Marcus
$115 → $75MaintainsOverweightGet Alert
04/25/2024Buy Now14.06%Wells Fargo
Vik Chopra
$98 → $77MaintainsEqual-WeightGet Alert
04/25/2024Buy Now40.72%Piper Sandler
Matt O'Brien
$100 → $95MaintainsOverweightGet Alert
04/25/2024Buy Now58.5%Needham
Mike Matson
$129 → $107MaintainsBuyGet Alert
02/01/2024Buy Now48.13%Piper Sandler
Matt O'Brien
$130 → $100MaintainsOverweightGet Alert
02/01/2024Buy Now70.35%JP Morgan
Robbie Marcus
$135 → $115MaintainsOverweightGet Alert
02/01/2024Buy Now45.16%Wells Fargo
Durgesh Chopra
$107 → $98MaintainsEqual-WeightGet Alert
02/01/2024Buy Now91.08%Needham
Mike Matson
$119 → $129MaintainsBuyGet Alert
10/27/2023Buy Now92.56%Piper Sandler
Matt O'Brien
$145 → $130MaintainsOverweightGet Alert
10/26/2023Buy Now77.75%Stifel
Rick Wise
$136 → $120MaintainsBuyGet Alert
10/26/2023Buy Now58.5%Wells Fargo
Durgesh Chopra
$123 → $107MaintainsEqual-WeightGet Alert
10/26/2023Buy Now76.27%Needham
Mike Matson
$140 → $119MaintainsBuyGet Alert
07/27/2023Buy Now114.78%JP Morgan
Robbie Marcus
$125 → $145MaintainsOverweightGet Alert
07/27/2023Buy Now107.38%Needham
Mike Matson
$139 → $140MaintainsBuyGet Alert
07/27/2023Buy Now108.86%Keybanc
Matthew Mishan
$131 → $141MaintainsOverweightGet Alert
07/24/2023Buy Now105.9%Needham
Mike Matson
 → $139ReiteratesBuy → BuyGet Alert
06/05/2023Buy Now105.9%Needham
Mike Matson
$135 → $139MaintainsBuyGet Alert
05/22/2023Buy Now107.38%CL King
Kristen Stewart
 → $140Initiates → BuyGet Alert
04/27/2023Buy Now92.56%Stifel
Rick Wise
$118 → $130MaintainsBuyGet Alert
04/27/2023Buy Now89.6%Piper Sandler
Matt O'Brien
$118 → $128MaintainsOverweightGet Alert
04/27/2023Buy Now76.27%Wells Fargo
Durgesh Chopra
$96 → $119MaintainsEqual-WeightGet Alert
04/27/2023Buy Now99.97%Needham
Mike Matson
$122 → $135MaintainsBuyGet Alert
04/27/2023Buy Now94.05%Keybanc
Matthew Mishan
$124 → $131MaintainsOverweightGet Alert
03/27/2023Buy Now83.68%Keybanc
Matthew Mishan
 → $124UpgradeSector Weight → OverweightGet Alert
02/03/2023Buy Now74.79%Piper Sandler
Matt O'Brien
$108 → $118MaintainsOverweightGet Alert
02/03/2023Buy Now80.71%Needham
Mike Matson
$106 → $122MaintainsBuyGet Alert
11/15/2022Buy Now57.01%Needham
Mike Matson
$90 → $106MaintainsBuyGet Alert
10/14/2022Buy Now33.31%Needham
Mike Matson
$123 → $90MaintainsBuyGet Alert
10/12/2022Buy Now25.91%Jefferies
Matthew Taylor
 → $85Initiates → HoldGet Alert
08/02/2022Buy Now82.2%Needham
Mike Matson
$127 → $123MaintainsBuyGet Alert
07/28/2022Buy Now74.79%Piper Sandler
Matt O'Brien
$160 → $118MaintainsOverweightGet Alert
07/28/2022Buy Now88.12%Needham
Mike Matson
$155 → $127MaintainsBuyGet Alert
06/23/2022Buy Now62.94%Stifel
Rick Wise
$160 → $110MaintainsBuyGet Alert
05/05/2022Buy Now129.6%Needham
Mike Matson
$150 → $155MaintainsBuyGet Alert
01/21/2022Buy Now122.19%Needham
Mike Matson
$158 → $150MaintainsBuyGet Alert
10/28/2021Buy Now134.04%Needham
Mike Matson
—MaintainsBuyGet Alert
10/06/2021Buy Now122.19%Needham
Mike Matson
—UpgradeHold → BuyGet Alert
07/15/2021Buy Now137%UBS——Initiates → BuyGet Alert

FAQ

Q

What is the target price for Conmed (CNMD) stock?

A

The latest price target for Conmed (NYSE:CNMD) was reported by Needham on May 6, 2024. The analyst firm set a price target for $107.00 expecting CNMD to rise to within 12 months (a possible 58.50% upside). 17 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Conmed (CNMD)?

A

The latest analyst rating for Conmed (NYSE:CNMD) was provided by Needham, and Conmed reiterated their buy rating.

Q

When was the last upgrade for Conmed (CNMD)?

A

The last upgrade for Conmed Corp happened on March 27, 2023 when Keybanc raised their price target to $124. Keybanc previously had a sector weight for Conmed Corp.

Q

When was the last downgrade for Conmed (CNMD)?

A

There is no last downgrade for Conmed.

Q

When is the next analyst rating going to be posted or updated for Conmed (CNMD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on May 6, 2024 so you should expect the next rating to be made available sometime around May 6, 2025.

Q

Is the Analyst Rating Conmed (CNMD) correct?

A

While ratings are subjective and will change, the latest Conmed (CNMD) rating was a reiterated with a price target of $107.00 to $107.00. The current price Conmed (CNMD) is trading at is $67.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch